Infinity Pharmaceuticals Ends Merger Agreement With MEI Pharma

Dow Jones

Jul 24, 2023

By Chris Wack

Infinity Pharmaceuticals said Monday that it has ended its merger agreement with MEI Pharma after MEI couldn't get stockholder approval of the deal.

The biotechnology company said MEI didn't obtain stockholder approval for the merger with Infinity at a special meeting Sunday, nor could MEI obtain approval for an adjournment of the special meeting.

In the process of attempting to obtain approval for the merger, which the MEI board supported, MEI was forced to contend with an unsolicited public proposal to acquire MEI by certain activist stockholders, who launched a public campaign to buy MEI at a significant discount to its cash on hand.

In an effort to conserve resources and preserve value for stockholders, Infinity's board and management team expect to undertake a series of cost-saving measures.

Infinity provided a conditional notice of termination to MEI indicating that it was terminating the merger agreement if MEI didn't obtain stockholder. As a result, Infinity may be entitled to reimbursement of certain expenses and fees of $1 million from MEI.

Infinity has the potential to receive an additional $4 million termination fee from MEI under certain circumstances outlined in the joint proxy statement/prospectus relating to the merger.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 24, 2023 08:49 ET (12:49 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2353383082"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2353383082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2353383082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-07-24 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2353383082","market":"nz","top_or_hot":-1,"title":"Infinity Pharmaceuticals Ends Merger Agreement With MEI Pharma","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INFI\">Infinity Pharmaceuticals</a> said Monday that it has ended its merger agreement with <a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> after MEI couldn't get stockholder approval of the deal. \n</p>\n<p>\n  The biotechnology company said MEI didn't obtain stockholder approval for the merger with Infinity at a special meeting Sunday, nor could MEI obtain approval for an adjournment of the special meeting. \n</p>\n<p>\n  In the process of attempting to obtain approval for the merger, which the MEI board supported, MEI was forced to contend with an unsolicited public proposal to acquire MEI by certain activist stockholders, who launched a public campaign to buy MEI at a significant discount to its cash on hand. \n</p>\n<p>\n  In an effort to conserve resources and preserve value for stockholders, Infinity's board and management team expect to undertake a series of cost-saving measures. \n</p>\n<p>\n  Infinity provided a conditional notice of termination to MEI indicating that it was terminating the merger agreement if MEI didn't obtain stockholder. As a result, Infinity may be entitled to reimbursement of certain expenses and fees of $1 million from MEI. \n</p>\n<p>\n  Infinity has the potential to receive an additional $4 million termination fee from MEI under certain circumstances outlined in the joint proxy statement/prospectus relating to the merger. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2023 08:49 ET (12:49 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Infinity Pharmaceuticals Ends Merger Agreement With MEI Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInfinity Pharmaceuticals Ends Merger Agreement With MEI Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-07-24 20:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INFI\">Infinity Pharmaceuticals</a> said Monday that it has ended its merger agreement with <a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> after MEI couldn't get stockholder approval of the deal. \n</p>\n<p>\n  The biotechnology company said MEI didn't obtain stockholder approval for the merger with Infinity at a special meeting Sunday, nor could MEI obtain approval for an adjournment of the special meeting. \n</p>\n<p>\n  In the process of attempting to obtain approval for the merger, which the MEI board supported, MEI was forced to contend with an unsolicited public proposal to acquire MEI by certain activist stockholders, who launched a public campaign to buy MEI at a significant discount to its cash on hand. \n</p>\n<p>\n  In an effort to conserve resources and preserve value for stockholders, Infinity's board and management team expect to undertake a series of cost-saving measures. \n</p>\n<p>\n  Infinity provided a conditional notice of termination to MEI indicating that it was terminating the merger agreement if MEI didn't obtain stockholder. As a result, Infinity may be entitled to reimbursement of certain expenses and fees of $1 million from MEI. \n</p>\n<p>\n  Infinity has the potential to receive an additional $4 million termination fee from MEI under certain circumstances outlined in the joint proxy statement/prospectus relating to the merger. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2023 08:49 ET (12:49 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEI","symbol_name":"Methode Electronics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2353383082","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2353383082","pubTimestamp":1690202940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Infinity Pharmaceuticals said Monday that it has ended its merger agreement with MEI Pharma after MEI couldn't get stockholder approval of the deal.The biotechnology company said MEI didn't obtain stockholder approval for the merger with Infinity at a special meeting Sunday, nor could MEI obtain approval for an adjournment of the special meeting.In the process of attempting to obtain approval for the merger, which the MEI board supported, MEI was forced to contend with an unsolicited public proposal to acquire MEI by certain activist stockholders, who launched a public campaign to buy MEI at a significant discount to its cash on hand.In an effort to conserve resources and preserve value for stockholders, Infinity's board and management team expect to undertake a series of cost-saving measures.Infinity provided a conditional notice of termination to MEI indicating that it was terminating the merger agreement if MEI didn't obtain stockholder. As a result, Infinity may be entitled to reim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MEI":"Methode Electronics Inc","BK4145":"电子制造服务","BK4139":"生物科技"},"translate_title":"Infinity Pharmaceuticals终止与MEI Pharma的合并协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEI":1,"INFI":1,"MEIP":1},"content_text":"By Chris Wack \n\n\n \n\n\nInfinity Pharmaceuticals said Monday that it has ended its merger agreement with MEI Pharma after MEI couldn't get stockholder approval of the deal. \n\n\n  The biotechnology company said MEI didn't obtain stockholder approval for the merger with Infinity at a special meeting Sunday, nor could MEI obtain approval for an adjournment of the special meeting. \n\n\n  In the process of attempting to obtain approval for the merger, which the MEI board supported, MEI was forced to contend with an unsolicited public proposal to acquire MEI by certain activist stockholders, who launched a public campaign to buy MEI at a significant discount to its cash on hand. \n\n\n  In an effort to conserve resources and preserve value for stockholders, Infinity's board and management team expect to undertake a series of cost-saving measures. \n\n\n  Infinity provided a conditional notice of termination to MEI indicating that it was terminating the merger agreement if MEI didn't obtain stockholder. As a result, Infinity may be entitled to reimbursement of certain expenses and fees of $1 million from MEI. \n\n\n  Infinity has the potential to receive an additional $4 million termination fee from MEI under certain circumstances outlined in the joint proxy statement/prospectus relating to the merger. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 24, 2023 08:49 ET (12:49 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}